Prospera Financial Services Inc Sells 2,571 Shares of Guardant Health, Inc. (NASDAQ:GH)

Prospera Financial Services Inc cut its holdings in shares of Guardant Health, Inc. (NASDAQ:GHGet Rating) by 67.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,221 shares of the company’s stock after selling 2,571 shares during the period. Prospera Financial Services Inc’s holdings in Guardant Health were worth $49,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its holdings in shares of Guardant Health by 7.1% in the first quarter. Teacher Retirement System of Texas now owns 17,806 shares of the company’s stock valued at $1,179,000 after purchasing an additional 1,177 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Guardant Health by 7.8% in the first quarter. Swiss National Bank now owns 204,300 shares of the company’s stock valued at $13,533,000 after purchasing an additional 14,800 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Guardant Health by 5.3% in the first quarter. American Century Companies Inc. now owns 1,057,870 shares of the company’s stock valued at $70,074,000 after purchasing an additional 52,772 shares in the last quarter. Integral Health Asset Management LLC increased its position in shares of Guardant Health by 285.3% in the second quarter. Integral Health Asset Management LLC now owns 385,291 shares of the company’s stock valued at $15,543,000 after acquiring an additional 285,291 shares during the last quarter. Finally, Sicart Associates LLC increased its position in shares of Guardant Health by 219.1% in the first quarter. Sicart Associates LLC now owns 133,666 shares of the company’s stock valued at $8,854,000 after acquiring an additional 91,783 shares during the last quarter. 89.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on GH. Cowen lowered their target price on Guardant Health from $110.00 to $83.00 in a research report on Friday, November 4th. Credit Suisse Group lowered their target price on Guardant Health from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, November 4th. Craig Hallum began coverage on Guardant Health in a research report on Wednesday, October 19th. They issued a “buy” rating and a $88.00 target price on the stock. Piper Sandler downgraded Guardant Health from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $65.00 to $50.00 in a research report on Tuesday, November 1st. Finally, Morgan Stanley lowered their target price on Guardant Health from $85.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $100.64.

Guardant Health Trading Up 6.2 %

Shares of NASDAQ:GH opened at $51.25 on Wednesday. Guardant Health, Inc. has a 12-month low of $27.65 and a 12-month high of $111.48. The stock has a market cap of $5.25 billion, a PE ratio of -8.64 and a beta of 0.63. The business has a 50 day moving average of $51.39 and a 200-day moving average of $47.25. The company has a quick ratio of 6.10, a current ratio of 6.46 and a debt-to-equity ratio of 6.82.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Further Reading

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.